U.S. Medicine Features bioAffinity's CyPath Lung Test For Enhanced VA Lung Cancer Detection And Cost Reduction

Benzinga·09/03/2025 12:13:48

Listen to the news

Noninvasive diagnostic can help federal medical system address veterans at higher risk for developing lung cancer

U.S. Medicine, a leading publication for federal healthcare professionals, has featured bioAffinity Technologies' CyPath® Lung in its pulmonary issue, highlighting the test's potential to improve lung cancer detection while lowering costs for the Department of Veterans Affairs (VA).

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English